AFT Pharmaceuticals

[lorraina]

Any one who wants "The Dinkum Oil" on AFT should go to the other channel, and look at Rawz's post # 1,046 on page 53 AFT thread.
The graph says it all.

[Left Field]

I think page 10 tells the story: consistently rising revenue creating flatlining earnings (well, with some ups and downs). EPS - hmm.

Clearly not an investment for you BP along with minimal dividends.  Best you shun AFT....

However, AFT's accounts are backward looking (as they always are.) For the last 10 or more years AFT have been spending roughly $10 mill pa on research. The accounts subscribe no value to this research. It is seen only as a cost.

The Pitt Research is the first attempt to look at a forward value or ROI on the past research. Pitt only looked at 3 of AFT's pipeline of 8 to 10 potential products in relation to the potential markets they address and came up with SP valuations more than double today's SP.

Lastly since 2022 AFT's SP slowly declined roughly 43% from $4.50 to a low around $2.60 in 2025..... however in 2026 the market (which is forward looking,) started to reassess AFT and the SP has risen over 60% to date (and some of us have been fortunate to share these recent gains.)

For investors who like overlooked, ignored and undervalued companies,  AFT is offers exciting potential....